COMP <GO>
CI vs ABBV // RSI-14 & 200D SMA MOMENTUM
The Cigna Group (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CI 4
— ABBV 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ABBV
LAST: $298.23 (-0.06%) • MKT CAP: $78.85B
rsi-technicals
55.6
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
rsi-technicals
72.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.80% | 70.20% | -48.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.80% | 29.00% | -20.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 33.3x | -27.20 | CI | /valuation <GO> |
| Free Cash Flow Yield | -3.51% | 3.47% | -6.98 | ABBV | /fcf-yield <GO> |
| Operating Margin | 3.30% | 24.60% | -21.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 2.20% | 6.90% | -4.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 11.20% | 8.60% | +2.60 | CI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.04% | 2.27% | -0.23 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.70 | 5.33 | -2.63 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.40% | -0.10 | CI | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 55.6 | 72.8 | -17.16 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.15 | -0.03 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.3x | 113.1x | -100.80 | CI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $78.85B | $513.86B | -$435.01B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CI REV | ABBV REV | CI GROSS % | ABBV GROSS % | CI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $274.90B | $61.16B | 21.8% | 70.2% | -$2.77B | $17.82B |
| FY 2024 | $247.12B | $56.33B | 26.1% | 70.0% | -$757.4M | $17.83B |
| FY 2023 | $195.26B | $54.32B | 44.0% | 44.0% | $3.03B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CI // BETA 1.12
ABBV // BETA 1.15